Stephen Schmitz

Stephen Schmitz, MD, MPH, possesses extensive experience in the field of pharmacovigilance and medical safety. Currently serving as the Vice President of Pharmacovigilance at Dragonfly Therapeutics, Inc., Stephen previously held the position of Chief Medical Officer at Ur24Technology, Inc. Additionally, Stephen has worked as Vice-President of Global Medical Safety at Kiniksa Pharmaceuticals and as Vice-President of Pharmacovigilance and Risk Management at Wave Life Sciences.